Efficacy of Treatments for Cholestatic Pruritus: A Systemic Review and Meta-analysis
Keywords:cholestatic itch, rifampicin, acid ursodesoxycholic systematic review
Cholestatic itch is a disabling symptom that may be secondary to liver or biliary diseases. Management of cholestatic pruritus is complex. A systematic review and meta-analysis on the efficacy of treatments for cholestatic pruritus were performed. PubMed and Cochrane Library were searched using the algorithm “(hepatitis OR cholestatic OR liver) AND (pruritus OR itch) AND (management OR treatment OR treatments)” for 1975–2019. Of the 2,264 articles identified, 93 were included in a systematic review and 15 in a meta-analysis (studies evaluating pruritus with a visual analogue scale). Some treatments act by reducing levels of pruritogens in the enterohepatic cycle, others modify the metabolism or secretion of these pruritogens, or act on pruritus pathways. A further possible treatment is albumin dialysis. However, due to many heterogeneities in the reviewed studies it is difficult to identify and recommend an optimum treatment. Only 15 studies were included in the meta-analysis, due to the small number of randomized studies using a visual analogue scale.
Misery L, Ständer S, editors. Pruritus. Cham: Springer International Publishing; 2016 [accessed 13 Apr 2020]. Avalable from: http: //link.springer.com/10.1007/978-3-319-33142-3.
Ständer S. Classification of itch. Curr Probl Dermatol 2016; 50: 1-4.
De Vloo C, Nevens F. Cholestatic pruritus: an update. Acta Gastro-Enterol Belg 2019; 82: 75-82.
Sun Y, Zhang W, Evans JF, Floreani A, Zou Z, Nishio Y, et al. Autotaxin, pruritus and primary biliary cholangitis (PBC). Autoimmun Revt 2016; 15: 795-800.
Kremer AE, Gonzales E, Schaap FG, Oude Elferink RPJ, Jacquemin E, Beuers U. Serum autotaxin activity correlates with pruritus in pediatric cholestatic disorders. J Pediatr Gastroenterol Nutr 2016; 62: 530-535.
Kremer AE, Martens JJWW, Kulik W, Ruëff F, Kuiper EMM, van Buuren HR, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010; 139: 1008-1018.
Düll MM, Kremer AE. Management of chronic hepatic itch. Dermatol Clin 2018; 36: 293-300.
Bhalerao A, Mannu GS. Management of pruritus in chronic liver disease. Dermatol Res Pract 2015; 2015: 295891.
Jin XY, Khan TM. Quality of life among patients suffering from cholestatic liver disease-induced pruritus: a systematic review. J Formos Med Assoc Taiwan Yi Zhi 2016; 115: 689-702.
Hegade VS, Mells GF, Fisher H, Kendrick S, DiBello J, Gilchrist K, et al. Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom. Clin Gastroenterol Hepatol 2019; 17: 1379-1387.e3.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67: 145-172.
Weisshaar E, Szepietowski JC, Dalgard FJ, Garcovich S, Gieler U, Giménez-Arnau AM, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol 2019; 99: 469-506.
Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005; 129: 894-901.
Di Padova C, Tritapepe R, Rovagnati P, Rossetti S. Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol 1984; 6: 773-776.
Yokomori H. Effects of ursodeoxycholic acid and colestilan versus ursodeoxycholic acid alone on serum bile acids and pruritus: a randomized, open-label study. 2001 [accessed Dec 15 2019]. Available from: https: //www.cochranelibrary.com/central/doi/10.1002/central/CN-00442075/full.
Kuiper EMM, van Erpecum KJ, Beuers U, Hansen BE, Thio HB, de Man RA, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatol Baltim Md 2010; 52: 1334-1340.
Hegade VS, Kendrick SFW, Dobbins RL, Miller SR, Thompson D, Richards D, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet Lond Engl 2017; 389: 1114-1123.
Mayo MJ, Pockros PJ, Jones D, Bowlus CL, Levy C, Patanwala I, et al. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun 2019; 3: 365-381.
Shneider BL, Spino C, Kamath BM, Magee JC, Bass LM, Setchell KD, et al. Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in alagille syndrome. Hepatol Commun 2018; 2: 1184-1198.
Al-Dury S, Wahlström A, Wahlin S, Langedijk J, Elferink RO, Ståhlman M, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep 2018; 8: 6658.
Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R, Loret-de-Mola O, Nahmad M, Burnweit CA. Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus. J Pediatr Surg 1998; 33: 220-224.
Modi BP, Suh MY, Jonas MM, Lillehei C, Kim HB. Ileal exclusion for refractory symptomatic cholestasis in Alagille syndrome. J Pediatr Surg 2007; 42: 800-805.
Jankowska I, Czubkowski P, Kaliciński P, Ismail H, Kowalski A, Ryżko J, et al. Ileal exclusion in children with progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2014; 58: 92-95.
Van Vaisberg V, Tannuri ACA, Lima FR, Tannuri U. Ileal exclusion for pruritus treatment in children with progressive familial intrahepatic cholestasis and other cholestatic diseases. J Pediatr Surg 2020; 55: 1385-1391.
Ramachandran P, Shanmugam NP, Sinani SA, Shanmugam V, Srinivas S, Sathiyasekaran M, et al. Outcome of partial internal biliary diversion for intractable pruritus in children with cholestatic liver disease. Pediatr Surg Int 2014; 30: 1045-1049.
Khan I, Qureshi MA, Karim F, Shaukat M. Surgical treatment for intractable pruritus in progressive familial intrahepatic cholestasis. JPMA J Pak Med Assoc 2018; 68: 953-955.
Whitington PF, Whitington GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 1988; 95: 130-136.
Ng VL, Ryckman FC, Porta G, Miura IK, de Carvalho E, Servidoni MF, et al. Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2000; 30: 152-156.
Ponsioen CY, Lam K, van Milligen de Wit AW, Huibregtse K, Tytgat GN. Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol 1999; 94: 2403-2407.
Hegade VS, Krawczyk M, Kremer AE, Kuczka J, Gaouar F, Kuiper EMM, et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment Pharmacol Ther 2016; 43: 294-302.
Battezzati PM, Podda M, Bianchi FB, Naccarato R, Orlandi F, Surrenti C, et al. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis: preliminary analysis of a double-blind multicenter trial. J Hepatol 1993; 17: 332-338.
Calmus Y, Poupon R. Ursodeoxycholic acid (UDCA) in the treatment of chronic cholestatic diseases. Biochimie 1991; 73: 1335-1338.
Pares A, Caballeria L, Rodes J, Bruguera M, Rodrigo L, Garcia-Plaza A et al . Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis results of a double-blind controlled muticentric trial. J Hepatol 2000; 32: 561-566
Diaferia A, Nicastri PL, Tartagni M, Loizzi P, Iacovizzi C, Di Leo A. Ursodeoxycholic acid therapy in pregnant women with cholestasis. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet 1996; 52: 133-140.
Floreani A, Paternoster D, Melis A, Grella PV. S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. Eur J Obstet Gynecol Reprod Biol 1996; 67: 109-113.
Joutsiniemi T, Timonen S, Leino R, Palo P, Ekblad U. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Arch Gynecol Obstet 2014; 289: 541-547.
Zhang L, Liu X-H, Qi H-B, Li Z, Fu X-D, Chen L, et al. Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. Eur Rev Med Pharmacol Sci 2015; 19: 3770-3776.
Chappell LC, Gurung V, Seed P, Chambers J, Williamson C, Thornton J. Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ 2012; 344: e3799
Roncaglia N, Locatelli A, Arreghini A, Assi F, Cameroni I, Pezzullo JC, et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG Int J Obstet Gynaecol 2004; 111: 17-21.
Jain AK, Waghmare C, Adkar S, Jain M, Sircar C, Chahwala F. The comparison of efficacy of ursodeoxycholic acid, ondandsetron and natrexone in the prupitus or acute cholestatic viral hepatitis. J Clin Exp Hepatol 2013; 3: S47.
Wunsch E, Trottier J, Milkiewicz M, Raszeja-Wyszomirska J, Hirschfield GM, Barbier O, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatol Baltim Md 2014; 60: 931-940.
Matsuzaki Y, Tanaka N, Osuga T, Aikawa T, Shoda J, Doi M, et al. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol 1990; 85: 15-23.
Floreani A, Mioni D, Chiaramonte M, Naccarato R. Double-blind, controlled study of tauroursodeoxycholic acid in elderly patients with hepatitis C virus-related cirrhosis. Curr Ther Res 1999; 60: 550-557.
Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94: 488-493.
Cynamon HA, Andres JM, Iafrate RP. Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology 1990; 98: 1013-1016.
Podesta A, Lopez P, Terg R, Villamil F, Flores D, Mastai R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991; 36: 216-220.
Ataei S, Kord L, Larki A, Yasrebifar F, Mehrpooya M, Seyedtabib M, et al. Comparison of sertraline with rifampin in the treatment of cholestatic pruritus: a randomized clinical trial. Rev Recent Clin Trials 2019; 14: 217-223.
Woolf GM, Reynolds TB. Failure of rifampin to relieve pruritus in chronic liver disease. J Clin Gastroenterol 1990; 12: 174-177.
Bachs L. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. 1989 [accessed 15 Dec 2019]. Available from: https: //www.cochranelibrary.com/central/doi/10.1002/central/CN-00058452/full.
Bachs L, Parés A, Elena M, Piera C, Rodés J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992; 102: 2077-2080.
Gregorio GV, Ball CS, Mowat AP, Mieli-Vergani G. Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. Arch Dis Child 1993; 69: 141-143.
Rahimpour S. Nasiri-Toosi M, Khalili H, Ebrahimi-Daryani N, Nouri-Taromlou MK, Azizi Z. A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. J Gastrointestin Liver Dis 2016; 25: 457-464
Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di Padova C. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study. Gastroenterology 1990; 99: 211-215.
Frezza M, Pozzato G, Chiesa L, Stramentinoli G, di Padova C. Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration. Hepatol Baltim Md 1984; 4: 274-278.
Wunsch E, Raszeja-Wyszomirska J, Barbier O, Milkiewicz M, Krawczyk M, Milkiewicz P. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study. J Gastrointest Liver Dis 2018; 27: 273-279.
Fiorelli G. S-Adenosylmethionine in the treatment of intrahepatic cholestasis of chronic liver disease: A field trial. Curr Ther Res 1999; 60: 335-348.
Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med 2018; 378: 2171-2181.
Reig A, Sesé P, Parés A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am J Gastroenterol 2018; 113: 49-55.
Lemoinne S, Pares A, Reig A, Ben Belkacem K, Kemgang Fankem AD, Gaouar F, et al. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. Clin Res Hepatol Gastroenterol 2018; 42: 521-528.
Kumada H, Miyakawa H, Muramatsu T, Ando N, Oh T, Takamori K, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol Res Off J Jpn Soc Hepatol 2017; 47: 972-982.
Akuta N, Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, et al. Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: preliminary prospective confirmatory trial. Hepatol Res Off J Jpn Soc Hepatol 2018; 48: 810-813.
Kamimura K, Yokoo T, Kamimura H, Sakamaki A, Abe S, Tsuchiya A, et al. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses. PloS One 2017; 12: e0178991.
Yagi M, Tanaka A, Namisaki T, Takahashi A, Abe M, Honda A, et al. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. J Gastroenterol 2018; 53: 1151-1158.
Akuta N, Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, et al. Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride. Hepatol Res Off J Jpn Soc Hepatol 2018; 48: 45-50.
Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113: 1264-1269.
Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh A-H, et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol WJG 2006; 12: 1125-1128.
Terg R, Coronel E, Sordá J, Muñoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37: 717-722.
Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102: 544-549.
Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995; 123: 161-167.
Joshi GG, Thakur BS, Sircar S, Namdeo A, Jain AK. Role of intravenous naloxone in severe pruritus of acute cholestasis. Indian J Gastroenterol Off J Indian Soc Gastroenterol 2009; 28: 180-182.
Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999; 41: 431-434.
Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatol Baltim Md 1998; 27: 679-684.
Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatol Baltim Md 2006; 44: 1317-1323.
Villamil AG, Bandi JC, Galdame OA, Gerona S, Gadano AC. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. Am J Med 2005; 118: 1160-1163.
Borgeat A, Wilder-Smith OH, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993; 104: 244-247.
Jones EA, Molenaar HAJ, Oosting J. Ondansetron and pruritus in chronic liver disease: a controlled study. Hepatogastroenterology 2007; 54: 1196-1199.
O'Donohue JW, Pereira SP, Ashdown AC, Haigh CG; Wilkison JR, Williams R. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther 2005; 21: 1041-1045.
Schwörer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995; 61: 33-37.
Müller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998; 10: 865-870.
Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatol Baltim Md 2007; 45: 666-674.
Thébaut A, Habes D, Gottrand F, Rivet C, Cohen J, Debray D, et al. Sertraline as an additional treatment for cholestatic pruritus in children. J Pediatr Gastroenterol Nutr 2017; 64: 431-435.
Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 2736-2741.
Doria C, Mandalá L, Smith J, Vitale CH, Lauro A, Gruttadauria S, et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2003; 9: 437-443.
Bellmann R, Graziadei IW, Feistritzer C, Schwaighofer H, Stellaard F, Sturm E, et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2004; 10: 107-114.
Montero JL, Pozo JC, Barrera P, Fraga E, Costán G, Domínguez JL, et al. Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). Transplant Proc 2006; 38: 2511-2513.
Novelli G, Rossi M, Poli L, Predagostini R, Iappelli M, Morabito V, et al. Intractable pruritus in patients with hepatitis C virus. Transplant Proc 2006; 38: 1089-1091.
Rifai K, Hafer C, Rosenau J, Athmann C, Haller H, Peter Manns M, et al. Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus). Scand J Gastroenterol 2006; 41: 1212-1217.
Parés A, Cisneros L, Salmerón JM, Caballería L, Mas A, Torras A, et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 1105-1110.
Parés A, Herrera M, Avilés J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 2010; 53: 307-312.
Leckie P, Tritto G, Mookerjee R, Davies N, Jones D, Jalan R. «Out-patient» albumin dialysis for cholestatic patients with intractable pruritus. Aliment Pharmacol Ther 2012; 35: 696-704.
Schaefer B, Schaefer F, Wittmer D, Engelmann G, Wenning D, Schmitt CP. Molecular adsorbents recirculating system dialysis in children with cholestatic pruritus. Pediatr Nephrol Berl Ger 2012; 27: 829-834.
Cisneros-Garza LE, Muñoz-Ramírez M del R, Muñoz-Espinoza LE, Ruiz Velasco JAV, Moreno-Alcántar R, Marín-López E, et al. The molecular adsorbent recirculating system as a liver support system: summary of Mexican experience. Ann Hepatol 2014; 13: 240-247.
Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, McGee M. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 2001; 96: 1563-1570.
Decock S, Roelandts R, Steenbergen WV, Laleman W, Cassiman D, Verslype C, et al. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. J Hepatol 2012; 57: 637-641.
Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut 1985; 26: 291-294.
Krawczyk M, Liebe R, Wasilewicz M, Wunsch E, Raszeja-Wyszomirska J, Milkiewicz P. Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch. Liver Int Off J Int Assoc Study Liver 2017; 37: 743-747.
Kittanamongkolchai W, El-Zoghby ZM, Eileen Hay J, Wiesner RH, Kamath PS, LaRusso NF, et al. Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease. Hepatol Int 2017; 11: 384-389.
Kaplan MM, Schmid C, Provenzale D, Sharma A, Dickstein G, McKusick A. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology 1999; 117: 1173-1180.
Hendrickse MT, Rigney E, Giaffer MH, Soomro I, Triger DR, Underwood JCE, et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 1999; 117: 400-407.
Babatin MA, Sanai FM, Swain MG. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Aliment Pharmacol Ther 2006; 24: 813-820.
Almasio PL, Floreani A, Chiaramonte M, Provenzano G, Battezzati P, Crosignani A, et al. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. Aliment Pharmacol Ther 2000; 14: 1645-1652.
van Hoogstraten HJ, Vleggaar FP, Boland GJ, van Steenbergen W, Griffioen P, Hop WC, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 2000; 95: 2015-2022.
Sherker AH, Vierling JM, Pockros P, Battish R, LaPlaca C, Resler M, et al. Oral Ast-120 (spherical carbon adsorbent) improves pruritus and lowers serum bile acidsin patients with cirrhosis of various etiologies. Hepatology 2009; 50: 462A-463A.
Watson JP, Jones DE, James OF, Cann PA, Bramble MG. Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study. J Gastroenterol Hepatol 1999; 14: 1034-1040.
Turner IB, Rawlins MD, Wood P, James OF. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. Aliment Pharmacol Ther 1994; 8: 337-342.
Düll MM, Kremer AE. Treatment of pruritus secondary to liver disease. Curr Gastroenterol Rep 2019; 21: 48.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267.
Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007; 102: 1528-1536.
Hoensch HP, Balzer K, Dylewizc P, Kirch W, Goebell H, Ohnhaus EE. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol 1985; 28: 475-477.
Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006; 26: 943-948.
Prince MI, Burt AD, Jones DEJ. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50: 436-439.
Kremer AE, Beuers U, Oude-Elferink RPJ, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs 2008; 68: 2163-2182.
Cheung AC, Patel H, Meza-Cardona J, Cino M, Sockalingam S, Hirschfield GM. Factors that influence health-related quality of life in patients with primary sclerosing cholangitis. Dig Dis Sci 2016; 61: 1692-1699.
GlaxoSmithKline. A Randomized, Double-blind, Multi-dose, Placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary biliary cholangitis (GLIMMER: GSK2330672 triaL of IBAT inhibition with multidose measurement for evaluation of response). clinicaltrials.gov; 2020 Apr [accessed 19 May 2020]. Report No.: NCT02966834. Available from: https: //clinicaltrials.gov/ct2/show/NCT02966834
GlaxoSmithKline. Long-term safety and tolerability study of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis. clinicaltrials.gov; 2020 avr [accessed 19 May 2020]. Report No.: NCT04167358. Available from: https: //clinicaltrials.gov/ct2/show/NCT04167358.
Bolier R, de Vries ES, Parés A, Helder J, Kemper EM, Zwinderman K, et al. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials 2017; 18: 230.
Ghosh S, Chaudhuri S. Intra-hepatic cholestasis of pregnancy: a comprehensive review. Indian J Dermatol 2013; 58: 327.
Gross CR, Malinchoc M, Kim WR, Evans RW, Wiesner RH, Petz JL, et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatol Baltim Md 1999; 29: 356-364.
Samuel D, Coilly A. Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation. BMC Med 2018; 16: 113.
Jagadisan B, Srivastava A. Child with jaundice and pruritus: how to evaluate? Indian J Pediatr 2016; 83: 1311-1320.
Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2012; 92: 497-501.
van Laarhoven AIM, van der Sman-Mauriks IM, Donders ART, Pronk MC, van de Kerkhof PCM, Evers AWM. Placebo effects on itch: a meta-analysis of clinical trials of patients with dermatological conditions. J Invest Dermatol 2015; 135: 1234-1243.
How to Cite
Copyright (c) 2022 Charles Dervout, Nicholas Boulais, Jean-Baptiste Nousbaum, Thomas Barnetche, Emilie Brenaut, Laurent Misery
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.